001     144995
005     20240321221018.0
024 7 _ |a 10.1002/pst.1992
|2 doi
024 7 _ |a pmid:31899854
|2 pmid
024 7 _ |a 1539-1604
|2 ISSN
024 7 _ |a 1539-1612
|2 ISSN
024 7 _ |a altmetric:73601015
|2 altmetric
037 _ _ |a DZNE-2020-00359
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Benda, Norbert
|0 P:(DE-HGF)0
|b 0
|e Corresponding author
245 _ _ |a Enrichment designs using placebo nonresponders.
260 _ _ |a New York, NY
|c 2020
|b Wiley
264 _ 1 |3 online
|2 Crossref
|b Wiley
|c 2020-01-03
264 _ 1 |3 print
|2 Crossref
|b Wiley
|c 2020-05-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1685015343_32156
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Enrichment designs that select placebo nonresponders have gained much attention during the last years in areas with high placebo response rates, eg, in depression. Proposals were made that re-randomize patients who did not respond to placebo during a first study phase as the sequential parallel design (SPD). This design uses in a second phase an enriched patient population where the treatment effect is expected to be more pronounced. This may be problematic if an effect in the overall population is claimed. Proposals were made to combine the treatment effects in the overall population from study phase 1 and the enriched population from study phase 2, alleviating but not solving the issue of a potential selection bias. This paper shows how this bias corresponding to the effect difference between the overall population and the enriched population depends on the variability of a potential subject-by-treatment interaction. Sample sizes are given, which lead to a significant result in the combining test with a given probability if actually the average effect in the overall population is zero. If, on the other hand, no subject-by-treatment interaction is given, the enrichment is shown to be inefficient. We conclude that enrichment designs using placebo nonresponders are not able to claim a positive average effect in the overall population if a subject-by-treatment interaction cannot be excluded. It cannot be used to demonstrate positive efficacy in the overall population in a pivotal phase III trial but may be used in early phases to demonstrate varying treatment effects between patients.
536 _ _ |a 345 - Population Studies and Genetics (POF3-345)
|0 G:(DE-HGF)POF3-345
|c POF3-345
|f POF III
|x 0
542 _ _ |i 2020-01-03
|2 Crossref
|u http://creativecommons.org/licenses/by-nc-nd/4.0/
542 _ _ |i 2020-01-03
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Data Interpretation, Statistical
|2 MeSH
650 _ 2 |a Double-Blind Method
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Models, Statistical
|2 MeSH
650 _ 2 |a Placebo Effect
|2 MeSH
650 _ 2 |a Randomized Controlled Trials as Topic: statistics & numerical data
|2 MeSH
650 _ 2 |a Research Design: statistics & numerical data
|2 MeSH
650 _ 2 |a Treatment Outcome
|2 MeSH
700 1 _ |a Hänisch, Britta
|0 P:(DE-2719)2810511
|b 1
|e Last author
|u dzne
773 1 8 |a 10.1002/pst.1992
|b : Wiley, 2020-01-03
|n 3
|p 303-314
|3 journal-article
|2 Crossref
|t Pharmaceutical Statistics
|v 19
|y 2020
|x 1539-1604
773 _ _ |a 10.1002/pst.1992
|g Vol. 19, no. 3, p. 303 - 314
|0 PERI:(DE-600)2083706-9
|n 3
|p 303-314
|t Pharmaceutical statistics
|v 19
|y 2020
|x 1539-1604
856 4 _ |u https://pub.dzne.de/record/144995/files/DZNE-2020-00359.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/144995/files/DZNE-2020-00359.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:144995
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)2810511
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-345
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Population Studies and Genetics
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-02-26
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2020-02-26
|w ger
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARM STAT : 2021
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-17
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-17
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2022-11-17
920 1 _ |0 I:(DE-2719)1013010
|k AG Hänisch ; AG Hänisch
|l Pharmacoepidemiology in Neurodegenerative Disorders
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1013010
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000069738
|2 Crossref
|o 10.1159/000069738
999 C 5 |y 2002
|2 Crossref
|o Sonawalla SB 2002
999 C 5 |9 -- missing cx lookup --
|a 10.1001/jama.287.14.1840
|2 Crossref
|o 10.1001/jama.287.14.1840
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000064813
|2 Crossref
|o 10.1159/000064813
999 C 5 |9 -- missing cx lookup --
|a 10.1136/bmj.311.7004.551
|2 Crossref
|o 10.1136/bmj.311.7004.551
999 C 5 |y 1999
|2 Crossref
|t Statistics in Medicine
|o ICH E9 Expert Working Group Statistics in Medicine 1999
999 C 5 |9 -- missing cx lookup --
|a 10.1038/npp.1994.63
|2 Crossref
|o 10.1038/npp.1994.63
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000332050
|2 Crossref
|o 10.1159/000332050
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.jpsychires.2015.01.007
|2 Crossref
|o 10.1016/j.jpsychires.2015.01.007
999 C 5 |9 -- missing cx lookup --
|a 10.4088/JCP.12m07670
|2 Crossref
|o 10.4088/JCP.12m07670
999 C 5 |9 -- missing cx lookup --
|a 10.1176/appi.ajp.2012.11071114
|2 Crossref
|o 10.1176/appi.ajp.2012.11071114
999 C 5 |9 -- missing cx lookup --
|a 10.4088/JCP.13m08947
|2 Crossref
|o 10.4088/JCP.13m08947
999 C 5 |9 -- missing cx lookup --
|a 10.1097/YIC.0000000000000039
|2 Crossref
|o 10.1097/YIC.0000000000000039
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.cct.2011.04.006
|2 Crossref
|o 10.1016/j.cct.2011.04.006
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.6116
|2 Crossref
|o 10.1002/sim.6116
999 C 5 |9 -- missing cx lookup --
|a 10.1177/1740774507081217
|2 Crossref
|o 10.1177/1740774507081217
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.4412
|2 Crossref
|o 10.1002/sim.4412
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.4292
|2 Crossref
|o 10.1002/sim.4292
999 C 5 |9 -- missing cx lookup --
|a 10.1177/0962280211431023
|2 Crossref
|o 10.1177/0962280211431023
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.6494
|2 Crossref
|o 10.1002/sim.6494
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.5728
|2 Crossref
|o 10.1002/sim.5728
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.conctc.2015.10.002
|2 Crossref
|o 10.1016/j.conctc.2015.10.002
999 C 5 |9 -- missing cx lookup --
|a 10.1080/10543406.2012.678234
|2 Crossref
|o 10.1080/10543406.2012.678234
999 C 5 |9 -- missing cx lookup --
|a 10.1002/9780470723586
|2 Crossref
|o 10.1002/9780470723586
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.6739
|2 Crossref
|o 10.1002/sim.6739
999 C 5 |9 -- missing cx lookup --
|a 10.1002/sim.2074
|2 Crossref
|o 10.1002/sim.2074
999 C 5 |y 2009
|2 Crossref
|t Multivariate Statistical Analysis
|o Mukhopadhyay P Multivariate Statistical Analysis 2009
999 C 5 |y 1994
|2 Crossref
|t Continuous Univariate Distributions, Volume 1
|o Johnson NL Continuous Univariate Distributions, Volume 1 1994


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21